Prelude Therapeutics Incorporated (PRLD) Stock Grade

About Prelude Therapeutics Incorporated's fundamentals

Prelude Therapeutics is a biotechnology company with a market capitalization of $222.6 million that is currently unprofitable, reporting a net loss and a net margin of -819.6% in its latest annual statement. The company is showing strong revenue momentum with year-over-year growth of 73.4%, indicating expanding business activity despite current losses. As a development-stage biotech firm, Prelude does not pay a dividend and traditional valuation metrics like P/E ratio and return on equity are not applicable. The company's financial profile reflects typical characteristics of early-stage therapeutics companies that invest heavily in research and development ahead of profitability.